3 quality blue chip ASX 200 shares analysts are tipping as buys

Here are three quality ASX 200 shares rated as buys…

| More on:
Person holding a blue chip.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors that are looking for some new shares to buy might want to look at the blue chips listed below.

These three blue chip ASX 200 shares have been tipped to climb meaningfully higher from where they trade today. Here's what you have to know about them:

CSL Limited (ASX: CSL)

The first blue chip for investors to look at is one of the world's leading biotechnology companies. CSL comprises the CSL Behring and Seqirus businesses, which are leaders in their respective fields – plasma therapies and vaccines. The company is also aiming to acquire Vifor Pharma in a blockbuster deal that will expand its product portfolio and pipeline. All in all, this deal, its billion-dollar per annum spend on R&D, and improving plasma collections, appear to have positioned CSL well for long term growth.

Yesterday the team at Citi retained its buy rating and $335.00 price target on CSL's shares. Its analysts believe that plasma collections will bounce back beyond pre-pandemic levels this year. Citi expects this to be a big boost to investor sentiment.

Goodman Group (ASX: GMG)

Another blue chip ASX 200 share that could be in the buy zone is Goodman. It is a global integrated commercial and industrial property company with a world class property portfolio. These properties have exposure to key growth markets such as ecommerce and are in high demand. Thanks to this strong demand and its lucrative development pipeline, Goodman has been tipped to continue its strong growth long into the future.

Citi is also positive on Goodman's future. Its analysts currently have a buy rating and $29.50 price target on its shares. The broker recently stated that it expects Goodman to outperform its upgraded earnings guidance in FY 2022.

ResMed Inc. (ASX: RMD)

A final blue chip ASX 200 share to look at is ResMed. It is a sleep treatment focused medical device company which has been tipped to continue its stellar growth long into the future. This is thanks to its world class products, significant market opportunity, the growing prevalence of sleep disorders, and, as Morgans highlights, its "unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain."

It is partly because of the latter that Morgans is positive on the company and has an add rating and $40.46 price target on its shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Blue Chip Shares

Man sits smiling at a computer showing graphs
Blue Chip Shares

3 ASX shares Australians can buy and hold for the next decade

Analysts think these high quality stocks could be in the buy zone right now.

Read more »

2 women looking at phone
Blue Chip Shares

3 high quality blue chip ASX 200 shares to buy in November

Here are a few blue chip shares that have been rated as buys this month by analysts.

Read more »

A businessman lights up the fifth star in a lineup, indicating positive share price for a top performer
Blue Chip Shares

2 of the highest-quality blue chip ASX 200 stocks money can buy

Analysts think these blue chips are top buys for investors right now. But why?

Read more »

Three smiling corporate people examine a model of a new building complex.
Blue Chip Shares

This blue chip ASX 200 stock is 'among the highest-quality names' under coverage

Goldman Sachs thinks this blue chip is a top buy.

Read more »

A business woman flexes her muscles overlooking a city scape below.
Blue Chip Shares

Brokers name 2 strong ASX 200 shares to buy now

These shares are among the top picks on the benchmark ASX 200 index according to analysts.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Blue Chip Shares

Up 47% in a year: This blue chip ASX 200 stock can keep rising

Bell Potter is feeling bullish about this stock. But why?

Read more »

A man looking at his laptop and thinking.
Blue Chip Shares

Should you buy Coles and Mineral Resources shares this month?

Are these blue chips buys? Let's see what Bell Potter is saying about them.

Read more »

Happy man working on his laptop.
Blue Chip Shares

These big ASX 200 blue chip shares could rise 20% to 50%

Analysts think these blue chips could be cheap at current levels.

Read more »